中国临床药理学杂志2025，Vol.41Issue(4)：565-569,5.DOI:10.13699/j.cnki.1001-6821.2025.04.024
拓扑异构酶Ⅱα与非小细胞肺癌预后及免疫浸润相关性的研究
Analysis of correlation between topoisomerase Ⅱ alpha and the prognosis and immune infiltration in non-small cell lung cancer
摘要
Abstract
Objective To analyze the correlations between topoisomerase Ⅱ alpha(TOP2A)and prognosis and immune infiltration in lung cancer.Methods The expression difference of TOP2A in lung cancer patients was examined by tumor immune estimation resource(TIMER)database.The prognostic value of TOP2A in lung cancer was evaluated using the Kaplan-Meier Plotter and PrognoScan databases.Additionally,the correlation between immune infiltration related gene marker sets and TOP2A expression was analyzed by TIMER database.The gene-gene and protein-protein interactions were determined using GeneMANIA and STRING for network construction,respectively.The possible regulatory network of TOP2A was explored by miRWalk and DIANA-LncBase v2 databases.Results The expression of TOP2A in lung adenocarcinoma(LUAD)and squamous cell carcinoma(LUSC)was significantly upregulated and high expression of TOP2A was significantly associated with reduced overall survival,first progression survival,and post-progression survival in lung cancer patients.TOP2A expression was significantly correlated with the infiltration of immune cells in lung cancer,including monocytes,neutrophils,tumor-associated macrophages,helper T cells 1,regulatory T cells,and exhausted T cells.The majority of genes or proteins associated with TOP2A were involved in the regulation of gene transcription and cell cycle.An lncRNA(ENSG00000279978)was identified as being related to the progression of LUAD and LUSC.Conclusion TOP2A is an immune infiltration-related prognostic biomarker for lung cancer and may serve as a potential therapeutic target.关键词
拓扑异构酶Ⅱα/肺癌/免疫浸润/预后/生物标志物Key words
topoisomerase Ⅱ alpha/lung cancer/immune infiltration/prognosis/biomarker分类
医药卫生引用本文复制引用
刘钟桧,朱青,刘新民,焦红梅..拓扑异构酶Ⅱα与非小细胞肺癌预后及免疫浸润相关性的研究[J].中国临床药理学杂志,2025,41(4):565-569,5.基金项目
北京大学第一医院交叉研究专项课题资助项目(2024IR40) （2024IR40）
